Home 禄 Business 禄 Manufacturing
Pharmaceutical cash deal agreed
Source: Agencies |
June 18, 2013, Tuesday
|
Print Edition
Print Edition
JOHNSON & Johnson said yesterday it would buy Aragon Pharmaceuticals, a private company that is running a mid-stage clinical trial for a prostate cancer drug, for US$650 million in cash upfront and a possible second payment of US$350 million if it meets certain milestones.
The deal does not include development of Aragon's treatment for breast cancer, which will be spun off into a separate company called Seragon Pharmaceuticals ahead of the deal and will be run by Aragon's chief executive. The acquisition includes Aragon's most advanced drug, ARN-509, which is now being evaluated as a treatment for prostate cancer, it said.
The deal does not include development of Aragon's treatment for breast cancer, which will be spun off into a separate company called Seragon Pharmaceuticals ahead of the deal and will be run by Aragon's chief executive. The acquisition includes Aragon's most advanced drug, ARN-509, which is now being evaluated as a treatment for prostate cancer, it said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
